Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. The FDA has approved Sarclisa ...
FRANKFURT (Reuters) -Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a ...
Some results have been hidden because they may be inaccessible to you